Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Publication
, Journal Article
MacDonald, MR; Petrie, MC; Varyani, F; Ostergren, J; Michelson, EL; Young, JB; Solomon, SD; Granger, CB; Swedberg, K; Yusuf, S; Pfeffer, MA ...
Published in: Eur Heart J
June 2008
AIMS: To determine whether the risk of adverse cardiovascular (CV) outcomes associated with diabetes differs in patients with low and preserved ejection fraction (EF) heart failure (HF). METHODS AND RESULTS: We analysed outcomes in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme which randomized 7599 patients with symptomatic HF and a broad range of EF. The prevalence of diabetes was 28.3% in patients with preserved EF (>40%) and 28.5% in those with low EF (
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eur Heart J
DOI
EISSN
1522-9645
Publication Date
June 2008
Volume
29
Issue
11
Start / End Page
1377 / 1385
Location
England
Related Subject Headings
- Treatment Outcome
- Tetrazoles
- Stroke Volume
- Prognosis
- Male
- Humans
- Heart Failure
- Female
- Epidemiologic Methods
- Diabetic Angiopathies
Citation
APA
Chicago
ICMJE
MLA
NLM
MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., … CHARM Investigators, . (2008). Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J, 29(11), 1377–1385. https://doi.org/10.1093/eurheartj/ehn153
MacDonald, Michael R., Mark C. Petrie, Fumi Varyani, Jan Ostergren, Eric L. Michelson, James B. Young, Scott D. Solomon, et al. “Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.” Eur Heart J 29, no. 11 (June 2008): 1377–85. https://doi.org/10.1093/eurheartj/ehn153.
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008 Jun;29(11):1377–85.
MacDonald, Michael R., et al. “Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.” Eur Heart J, vol. 29, no. 11, June 2008, pp. 1377–85. Pubmed, doi:10.1093/eurheartj/ehn153.
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJV, CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008 Jun;29(11):1377–1385.
Published In
Eur Heart J
DOI
EISSN
1522-9645
Publication Date
June 2008
Volume
29
Issue
11
Start / End Page
1377 / 1385
Location
England
Related Subject Headings
- Treatment Outcome
- Tetrazoles
- Stroke Volume
- Prognosis
- Male
- Humans
- Heart Failure
- Female
- Epidemiologic Methods
- Diabetic Angiopathies